Identification
NameOxaliplatin
Accession NumberDB00526  (APRD00186)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility. Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin®.

Structure
Thumb
Synonyms
Diaminocyclohexane Oxalatoplatinum
L-OHP
Oxalatoplatin
Oxalatoplatinum
oxaliplatine
oxaliplatino
oxaliplatinum
External IDs JM-83 / NSC-266046 / RP-54780 / SR-96669
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act OxaliplatinPowder, for solution50 mgIntravenousActavis Pharma CompanyNot applicableNot applicableCanada
Act OxaliplatinPowder, for solution100 mgIntravenousActavis Pharma CompanyNot applicableNot applicableCanada
Act OxaliplatinSolution5 mgIntravenousActavis Pharma Company2015-12-16Not applicableCanada
EloxatinInjection, solution, concentrate5 mg/mLIntravenousSanofi Aventis2006-06-02Not applicableUs
EloxatinPowder, for solution100 mgIntravenousSanofi Aventis2008-06-272016-08-04Canada
EloxatinInjection, solution, concentrate5 mg/mLIntravenousAventis Pharma Ltd.2009-07-22Not applicableUs
EloxatinInjection, solution, concentrate5 mg/mLIntravenousSanofi Aventis2006-06-02Not applicableUs
EloxatinSolution5 mgIntravenousSanofi Aventis2007-07-17Not applicableCanada
EloxatinPowder, for solution50 mgIntravenousSanofi Aventis2008-06-272016-08-03Canada
OxaliplatinInjection, solution, concentrate50 mg/10mLIntravenousTeva Parenteral Medicines, Inc.2009-08-11Not applicableUs
OxaliplatinInjection, solution, concentrate100 mg/20mLIntravenousAPP Pharmaceuticals, Inc.2014-09-082017-05-31Us
OxaliplatinInjection, solution, concentrate5 mg/mLIntravenousWinthrop U.S.2014-07-07Not applicableUs
OxaliplatinSolution5 mgIntravenousPfizer2015-12-17Not applicableCanada
OxaliplatinInjection, solution, concentrate100 mg/20mLIntravenousTeva Parenteral Medicines, Inc.2009-08-11Not applicableUs
OxaliplatinInjection, solution, concentrate5 mg/mLIntravenousWinthrop U.S.2015-09-01Not applicableUs
OxaliplatinInjection, solution, concentrate50 mg/10mLIntravenousAPP Pharmaceuticals, Inc.2014-09-082016-03-31Us
OxaliplatinInjection, solution, concentrate5 mg/mLIntravenousWinthrop U.S.2014-07-07Not applicableUs
OxaliplatinInjection, solution, concentrate5 mg/mLIntravenousWinthrop U.S.2015-09-01Not applicableUs
Oxaliplatin for InjectionPowder, for solution100 mgIntravenousHospira, Inc.Not applicableNot applicableCanada
Oxaliplatin for InjectionPowder, for solution50 mgIntravenousHospira, Inc.Not applicableNot applicableCanada
Oxaliplatin InjectionSolution5 mgIntravenousSandoz Canada Incorporated2015-12-17Not applicableCanada
Oxaliplatin InjectionSolution5.0 mgIntravenousHospira, Inc.Not applicableNot applicableCanada
Oxaliplatin InjectionSolution5 mgIntravenousGeneric Medical Partners IncNot applicableNot applicableCanada
Oxaliplatin InjectionSolution5 mgIntravenousTeva2015-12-16Not applicableCanada
Oxaliplatin InjectionSolution5 mgIntravenousAccord Healthcare Limited2016-01-02Not applicableCanada
Oxaliplatin InjectionSolution5 mgIntravenousApotex CorporationNot applicableNot applicableCanada
Oxaliplatin Injection USPSolution5 mgIntravenousMylan PharmaceuticalsNot applicableNot applicableCanada
Oxaliplatin Injection, USPSolution5 mgIntravenousDr Reddy's LaboratoriesNot applicableNot applicableCanada
PMS-oxaliplatinSolution5 mgIntravenousPharmascience Inc2015-12-16Not applicableCanada
Taro-oxaliplatinSolution5 mgIntravenousTaro Pharmaceuticals, Inc.2017-02-15Not applicableCanada
Teva-oxaliplatin InjectionSolution5 mgIntravenousTevaNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
OxaliplatinInjection, solution5 mg/mLIntravenousGland Pharma Limited2017-02-20Not applicableUs
OxaliplatinInjection, solution, concentrate50 mg/10mLIntravenousSun Pharma Global FZE2014-04-09Not applicableUs
OxaliplatinInjection, solution5 mg/mLIntravenousMylan Institutional2012-08-09Not applicableUs
OxaliplatinPowder, for solution50 mg/10mLIntravenousPfizer Laboratories Div Pfizer Inc.2012-08-09Not applicableUs
OxaliplatinInjection5 mg/mLIntravenousNorth Star Rx Llc2017-06-15Not applicableUs
OxaliplatinInjection, solution5 mg/mLIntravenousSanja Pharmaceuticals Company2017-09-21Not applicableUs
OxaliplatinInjection, powder, lyophilized, for solution5 mg/mLIntravenousHospira, Inc.2009-09-30Not applicableUs
OxaliplatinPowder, for solution50 mg/10mLIntravenousMylan Institutional2012-08-09Not applicableUs
OxaliplatinInjection, solution5 mg/mLIntravenousGland Pharma Limited2017-02-20Not applicableUs
OxaliplatinInjection, solution5 mg/mLIntravenousMylan Institutional2012-08-09Not applicableUs
OxaliplatinInjection, solution100 mg/20mLIntravenousBreckenridge Pharmaceutical, Inc.2017-02-20Not applicableUs
OxaliplatinInjection, solution5 mg/mLIntravenousAlvogen, Inc.2017-07-31Not applicableUs
OxaliplatinInjection, solution50 mg/10mLIntravenousQilu Pharmaceuticals Co. Ltd2016-06-07Not applicableUs
OxaliplatinPowder, for solution100 mg/20mLIntravenousPfizer Laboratories Div Pfizer Inc.2012-08-09Not applicableUs
OxaliplatinInjection, powder, lyophilized, for solution100 mg/20mLIntravenousSun Pharma Global FZE2009-08-19Not applicableUs
OxaliplatinInjection5 mg/mLIntravenousCipla Limited2017-02-10Not applicableUs
OxaliplatinInjection, solution, concentrate5 mg/mLIntravenousHospira, Inc.2009-08-07Not applicableUs
OxaliplatinInjection, powder, lyophilized, for solution5 mg/mLIntravenousActavis Pharma Company2015-01-05Not applicableUs
OxaliplatinInjection, powder, lyophilized, for solution5 mg/mLIntravenousSagent Pharmaceuticals2012-08-09Not applicableUs
OxaliplatinInjection, solution5 mg/mLIntravenousAthenex Pharmaceutical Division, Llc.2017-03-15Not applicableUs
OxaliplatinInjection, solution, concentrate100 mg/20mLIntravenousSun Pharma Global FZE2014-04-09Not applicableUs
OxaliplatinInjection, solution5 mg/mLIntravenousSandoz2016-07-01Not applicableUs
OxaliplatinInjection, solution5 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2012-08-09Not applicableUs
OxaliplatinInjection5 mg/mLIntravenousNorth Star Rx Llc2017-06-15Not applicableUs
OxaliplatinInjection, solution, concentrate5 mg/mLIntravenousFresenius Kabi2010-06-11Not applicableUs
OxaliplatinPowder, for solution100 mg/20mLIntravenousMylan Institutional2012-08-09Not applicableUs
OxaliplatinInjection, powder, lyophilized, for solution50 mg/10mLIntravenousGland Pharma Limited2017-05-29Not applicableUs
OxaliplatinInjection, powder, lyophilized, for solution50 mg/10mLIntravenousBreckenridge Pharmaceutical, Inc.2017-09-01Not applicableUs
OxaliplatinInjection, solution100 mg/20mLIntravenousQilu Pharmaceuticals Co. Ltd2016-06-07Not applicableUs
OxaliplatinInjection, solution5 mg/mLIntravenousSandoz2015-03-01Not applicableUs
OxaliplatinInjection5 mg/mLIntravenousCipla Limited2017-02-10Not applicableUs
OxaliplatinInjection, solution5 mg/mLIntravenousSanja Pharmaceuticals Company2017-09-21Not applicableUs
OxaliplatinInjection, powder, lyophilized, for solution5 mg/mLIntravenousHospira, Inc.2009-09-30Not applicableUs
OxaliplatinInjection, powder, lyophilized, for solution5 mg/mLIntravenousSagent Pharmaceuticals2012-08-09Not applicableUs
OxaliplatinInjection, solution50 mg/10mLIntravenousBreckenridge Pharmaceutical, Inc.2017-02-20Not applicableUs
OxaliplatinInjection, solution5 mg/mLIntravenousAlvogen, Inc.2017-07-31Not applicableUs
OxaliplatinInjection, solution5 mg/mLIntravenousSandoz2016-07-01Not applicableUs
OxaliplatinInjection, solution5 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2012-08-09Not applicableUs
OxaliplatinInjection, powder, lyophilized, for solution50 mg/10mLIntravenousSun Pharma Global FZE2009-08-19Not applicableUs
OxaliplatinInjection, solution5 mg/mLIntravenousApotex Corporation2017-01-04Not applicableUs
OxaliplatinInjection, solution5 mg/mLIntravenousSagent Pharmaceuticals2014-09-15Not applicableUs
OxaliplatinInjection, solution200 mg/40mLIntravenousQilu Pharmaceuticals Co. Ltd2016-06-07Not applicableUs
OxaliplatinInjection, solution5 mg/mLIntravenousSandoz2015-03-01Not applicableUs
OxaliplatinInjection, powder, lyophilized, for solution100 mg/20mLIntravenousGland Pharma Limited2017-05-29Not applicableUs
OxaliplatinInjection, powder, lyophilized, for solution100 mg/20mLIntravenousBreckenridge Pharmaceutical, Inc.2017-09-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII04ZR38536J
CAS number61825-94-3
WeightAverage: 397.294
Monoisotopic: 397.060149
Chemical FormulaC8H14N2O4Pt
InChI KeyZROHGHOFXNOHSO-BNTLRKBRSA-L
InChI
InChI=1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1
IUPAC Name
(3aR,7aR)-octahydro-2',5'-dioxaspiro[cyclohexa[d]1,3-diaza-2-platinacyclopentane-2,1'-cyclopentane]-3',4'-dione
SMILES
[H][N]1([H])[[email protected]@H]2CCCC[[email protected]]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Pharmacology
Indication

Used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.

Structured Indications
Pharmacodynamics

Oxaliplatin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Oxaliplatin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.

Mechanism of action

Oxaliplatin undergoes nonenzymatic conversion to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. After activation, oxaliplatin binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and transcription. Cytotoxicity is cell-cycle nonspecific.

TargetKindPharmacological actionActionsOrganismUniProt ID
DNANucleotideyes
cross-linking/alkylation
Humannot applicabledetails
Related Articles
Absorption

Bioavailability is complete following intravenous administration. When a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m^2 is given, the peak serum concentration was 0.814 mcg/mL.

Volume of distribution
  • 440 L [single 2-hour IV infusion at dose of 85 mg/m^2] At the end of a 2-hour infusion of oxaliplatin, approximately 15% of the administered platinum is present in the systemic circulation. The remaining 85% is rapidly distributed into tissues or eliminated in the urine.
Protein binding

Plasma protein binding of platinum (active metabolite) is irreversible and is greater than 90%, primarily to albumin and gamma-globulins. It is also irreversibly binds to erythrocytes.

Metabolism

Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. There is no evidence of cytochrome P450-mediated metabolism in vitro.

Route of elimination

The major route of platinum elimination is renal excretion. At five days after a single 2-hour infusion of oxaliplatin, urinary elimination accounted for about 54% of the platinum eliminated, with fecal excretion accounting for only about 2%.

Half life

The decline of ultrafilterable platinum levels following oxaliplatin administartion is triphasic, with two distribution phases: t1/2α; 0.43 hours and t1/2β; 16.8 hours. This is followed by a long terminal elimination phase that lasts 391 hours (t1/2γ).

Clearance
  • 10 - 17 L/h [renal clearance]
Toxicity

There have been five cases of oxaliplatin overdose reported. One patient received two 130 mg/m2 doses of oxaliplatin (cumulative dose of 260 mg/m2) within a 24-hour period. The patient experienced Grade 4 thrombocytopenia (<25,000/mm3) without any bleeding, which resolved. Two other patients were mistakenly administered oxaliplatin instead of carboplatin. One patient received a total oxaliplatin dose of 500 mg and the other received 650 mg. The first patient experienced dyspnea, wheezing, paresthesia, profuse vomiting and chest pain on the day of administration. She developed respiratory failure and severe bradycardia, and subsequently did not respond to resuscitation efforts. The other patient also experienced dyspnea, wheezing, paresthesia, and vomiting. Most common adverse reactions (incidence ≥ 40%) were peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, nausea, increase in transaminases and alkaline phosphatase, diarrhea, emesis, fatigue and stomatitis.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Oxaliplatin can be increased when it is combined with Abiraterone.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Oxaliplatin.Approved
AzithromycinThe metabolism of Oxaliplatin can be decreased when combined with Azithromycin.Approved
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Oxaliplatin.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Oxaliplatin.Approved, Investigational
BortezomibThe metabolism of Oxaliplatin can be decreased when combined with Bortezomib.Approved, Investigational
BupropionThe serum concentration of Oxaliplatin can be increased when it is combined with Bupropion.Approved
CabazitaxelOxaliplatin may increase the myelosuppressive activities of Cabazitaxel.Approved
CaffeineThe metabolism of Oxaliplatin can be decreased when combined with Caffeine.Approved
CarbamazepineThe metabolism of Oxaliplatin can be increased when combined with Carbamazepine.Approved, Investigational
CitalopramThe metabolism of Oxaliplatin can be decreased when combined with Citalopram.Approved
ClotrimazoleThe metabolism of Oxaliplatin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with Clozapine.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Oxaliplatin.Approved, Investigational
Cyproterone acetateThe serum concentration of Oxaliplatin can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DeferasiroxThe serum concentration of Oxaliplatin can be increased when it is combined with Deferasirox.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Oxaliplatin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Oxaliplatin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Oxaliplatin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Oxaliplatin.Approved
DisulfiramThe metabolism of Oxaliplatin can be decreased when combined with Disulfiram.Approved
DocetaxelOxaliplatin may increase the myelosuppressive activities of Docetaxel.Approved, Investigational
EltrombopagThe serum concentration of Oxaliplatin can be increased when it is combined with Eltrombopag.Approved
FingolimodOxaliplatin may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluvoxamineThe metabolism of Oxaliplatin can be decreased when combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe serum concentration of Fosphenytoin can be decreased when it is combined with Oxaliplatin.Approved
G17DTThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with G17DT.Investigational
GI-5005The risk or severity of adverse effects can be increased when Oxaliplatin is combined with GI-5005.Investigational
INGN 201The risk or severity of adverse effects can be increased when Oxaliplatin is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Oxaliplatin is combined with INGN 225.Investigational
IsoniazidThe metabolism of Oxaliplatin can be decreased when combined with Isoniazid.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with Leflunomide.Approved, Investigational
LidocaineThe metabolism of Oxaliplatin can be decreased when combined with Lidocaine.Approved, Vet Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Oxaliplatin.Withdrawn
MexiletineThe metabolism of Oxaliplatin can be decreased when combined with Mexiletine.Approved
NatalizumabThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with Natalizumab.Approved, Investigational
NevirapineThe metabolism of Oxaliplatin can be decreased when combined with Nevirapine.Approved
NicotineThe metabolism of Oxaliplatin can be decreased when combined with Nicotine.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Oxaliplatin.Experimental
OsimertinibThe serum concentration of Oxaliplatin can be decreased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Oxaliplatin.Approved
PaclitaxelOxaliplatin may increase the myelosuppressive activities of Paclitaxel.Approved, Vet Approved
Peginterferon alfa-2bThe serum concentration of Oxaliplatin can be increased when it is combined with Peginterferon alfa-2b.Approved
PhenobarbitalThe metabolism of Oxaliplatin can be increased when combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Oxaliplatin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxaliplatin.Approved, Investigational
PrimidoneThe metabolism of Oxaliplatin can be increased when combined with Primidone.Approved, Vet Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with Rabies vaccine.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Oxaliplatin.Approved
RifampicinThe metabolism of Oxaliplatin can be increased when combined with Rifampicin.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with CDX-110.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Oxaliplatin.Approved
RolapitantThe serum concentration of Oxaliplatin can be increased when it is combined with Rolapitant.Approved
RopiniroleThe metabolism of Oxaliplatin can be decreased when combined with Ropinirole.Approved, Investigational
SimeprevirThe metabolism of Oxaliplatin can be decreased when combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Oxaliplatin.Approved
SRP 299The risk or severity of adverse effects can be increased when Oxaliplatin is combined with SRP 299.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Oxaliplatin.Approved, Investigational
Tenofovir disoproxilThe metabolism of Oxaliplatin can be decreased when combined with Tenofovir.Approved, Investigational
TeriflunomideThe serum concentration of Oxaliplatin can be decreased when it is combined with Teriflunomide.Approved
TG4010The risk or severity of adverse effects can be increased when Oxaliplatin is combined with TG4010.Investigational
TheophyllineThe metabolism of Oxaliplatin can be decreased when combined with Theophylline.Approved
TiclopidineThe metabolism of Oxaliplatin can be decreased when combined with Ticlopidine.Approved
TofacitinibOxaliplatin may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TopotecanThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with Topotecan.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Oxaliplatin.Approved, Investigational
VemurafenibThe serum concentration of Oxaliplatin can be increased when it is combined with Vemurafenib.Approved
Food InteractionsNot Available
References
Synthesis Reference

Masazumi Eriguchi, "Liposome preparations containing oxaliplatin." U.S. Patent US20040022842, issued February 05, 2004.

US20040022842
General References
  1. Pasetto LM, D'Andrea MR, Rossi E, Monfardini S: Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol. 2006 Aug;59(2):159-68. Epub 2006 Jun 27. [PubMed:16806962 ]
  2. Graham J, Mushin M, Kirkpatrick P: Oxaliplatin. Nat Rev Drug Discov. 2004 Jan;3(1):11-2. [PubMed:14756144 ]
External Links
ATC CodesL01XA03 — Oxaliplatin
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (2.35 MB)
MSDSDownload (38.4 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentStage IV Breast Cancer1
0RecruitingTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Carcinoma / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer / Unresectable Pancreatic Carcinoma1
1Active Not RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IV Pancreatic Cancer1
1Active Not RecruitingTreatmentAdvanced Cancers1
1Active Not RecruitingTreatmentAdvanced Solid Tumor Malignancies1
1Active Not RecruitingTreatmentCancer of Colon / Cancer of Pancreas / Colon Carcinoma / Colorectal Cancers / Malignant Neoplasm of Large Intestine / Malignant Neoplasm of Pancreas / Malignant Tumor of Colon / Neoplasms, Pancreatic1
1Active Not RecruitingTreatmentCancer, Breast / Cancer, Ovarian / Carcinoma, Colorectal / Carcinoma, Pancreatic / Melanoma / Non-Small Cell Lung Carcinoma (NSCLC) / Prostate Cancer / Renal Cell Adenocarcinoma / Tumors, Solid1
1Active Not RecruitingTreatmentCancers1
1Active Not RecruitingTreatmentColorectal Cancers2
1Active Not RecruitingTreatmentColorectal Cancers / Metastatic Cancers1
1Active Not RecruitingTreatmentEsophageal Cancers / Malignant Neoplasm of Cardio-esophageal Junction of Stomach1
1Active Not RecruitingTreatmentEsophageal Cancers / Neoplasms, Esophageal1
1Active Not RecruitingTreatmentGastric Adenocarcinoma / Gastroesophageal Junction Adenocarcinoma1
1Active Not RecruitingTreatmentMalignant Digestive System Neoplasm1
1Active Not RecruitingTreatmentMalignant Neoplasm of Colon / Rectal Carcinoma1
1Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas2
1Active Not RecruitingTreatmentMucinous Adenocarcinoma of the Rectum / Rectal Adenocarcinoma / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Rectum / Stage IIA Rectal Cancer / Stage IIA to IIIC Rectal Cancer / Stage IIB Rectal Cancer / Stage IIC Rectal Cancer / Stage IIIA Rectal Cancer / Stage IIIB Rectal Cancer / Stage IIIC Rectal Cancer1
1Active Not RecruitingTreatmentNeoplasms, Colorectal1
1Active Not RecruitingTreatmentNeoplasms / Solid Cancers1
1Active Not RecruitingTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
1Active Not RecruitingTreatmentTumors, Solid1
1CompletedTreatmentAdenocarcinoma of the Esophagus / Adenocarcinoma of the Stomach / Adenocarcinomas of the Gastroesophageal Junction / Squamous Cell Carcinoma of the Esophagus / Stage II Esophageal Cancer / Stage II Gastric Cancer / Stage III Esophageal Cancer / Stage III Gastric Cancer1
1CompletedTreatmentAdenocarcinoma of the Rectum / Mucinous Adenocarcinoma of the Rectum / Signet Ring Adenocarcinoma of the Rectum / Stage IIA Rectal Cancer / Stage IIB Rectal Cancer / Stage IIC Rectal Cancer / Stage IIIA Rectal Cancer / Stage IIIB Rectal Cancer / Stage IIIC Rectal Cancer1
1CompletedTreatmentAdenocarcinomas / Malignant Neoplasm of Pancreas / Neoplasms, Pancreatic1
1CompletedTreatmentAdult Solid Neoplasm / Hematopoietic and Lymphoid Cell Neoplasm1
1CompletedTreatmentAdvanced Cancers2
1CompletedTreatmentAdvanced Colorectal Cancer / Metastatic Colorectal Cancers / Neoplasms, Colorectal / Responsive to Fluoropyrimidines1
1CompletedTreatmentAdvanced Colorectal Carcinoma1
1CompletedTreatmentAdvanced Gastrointestinal Malignancies / Tumors, Solid1
1CompletedTreatmentAdvanced Incurable Solid Malignancy1
1CompletedTreatmentAdvanced Pancreatic Cancer1
1CompletedTreatmentAdvanced Solid Tumors2
1CompletedTreatmentAdvanced Solid Tumors / Hepatocellular,Carcinoma1
1CompletedTreatmentAdvanced Solid Tumors / Liver Cancer1
1CompletedTreatmentAdvanced Solid Tumors / Metastatic Colorectal Cancers / Pancreatic Cancer Metastatic1
1CompletedTreatmentAnal Carcinoma / Carcinoid tumour of the gastrointestinal tract / Colorectal Cancers / Esophageal Cancers / Extrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach / Small Intestine Cancer1
1CompletedTreatmentAnal, Colon, and Rectal Cancers / Colon/Rectal Cancer / Neoplasms, Colorectal1
1CompletedTreatmentCancer, Advanced / Liver Cancer1
1CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
1CompletedTreatmentCancers1
1CompletedTreatmentCancers / Pancreas1
1CompletedTreatmentCancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentCarcinoma of the Appendix / Colorectal Cancers / Primary Peritoneal Cavity Cancer1
1CompletedTreatmentCarcinoma of the Appendix / Colorectal Cancers / Small Intestine Cancer1
1CompletedTreatmentChildhood Burkitt Lymphoma / Childhood Central Nervous System Germ Cell Tumor / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Liver Cancer / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Medulloblastoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway Glioma / Recurrent Colon Cancer / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Melanoma / Recurrent Nasopharyngeal Cancer / Recurrent Neuroblastoma / Recurrent Osteosarcoma / Recurrent Wilms Tumor and Other Childhood Kidney Tumors / Recurrent/Refractory Childhood Hodgkin Lymphoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentChildhood Central Nervous System Choriocarcinoma / Childhood Central Nervous System Embryonal Tumor / Childhood Central Nervous System Germ Cell Tumor / Childhood Central Nervous System Germinoma / Childhood Central Nervous System Mixed Germ Cell Tumor / Childhood Central Nervous System Teratoma / Childhood Central Nervous System Yolk Sac Tumor / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Central Nervous System Embryonal Tumor / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentColorectal Cancers5
1CompletedTreatmentColorectal Cancers / Diarrhea / Neutropenias1
1CompletedTreatmentColorectal Cancers / Lung Cancers1
1CompletedTreatmentColorectal Cancers / Metastatic Cancers1
1CompletedTreatmentColorectal Liver Metastases1
1CompletedTreatmentEsophageal Cancers1
1CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer / Malignant Neoplasm of Pancreas / Periampullary Adenocarcinoma / Small Intestine Cancer1
1CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Malignant Neoplasm of Pancreas1
1CompletedTreatmentGastric cancer stage IV1
1CompletedTreatmentHepatocellular,Carcinoma1
1CompletedTreatmentKidney Diseases / Neoplasms / Neoplasms Metastasis1
1CompletedTreatmentLiver Diseases1
1CompletedTreatmentMalignant Lymphomas / Tumors, Solid1
1CompletedTreatmentMalignant Neoplasm of Stomach1
1CompletedTreatmentMetastatic Colorectal Cancers / Tumors, Solid1
1CompletedTreatmentMucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IIIA Colon Cancer / Stage IIIA Rectal Cancer / Stage IIIB Colon Cancer / Stage IIIB Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
1CompletedTreatmentNeoplasms, Gastrointestinal1
1CompletedTreatmentNeoplasms, Pancreatic2
1CompletedTreatmentPancreatic Cancer Metastatic1
1CompletedTreatmentPatients With Advanced or Metastatic Solid Tumors1
1CompletedTreatmentPeritoneal Cancer1
1CompletedTreatmentPeritoneal Cavity Cancer1
1CompletedTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage III Colon Cancer / Stage III Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentStomach Neoplasms2
1CompletedTreatmentUnresectable Colorectal Liver Metastases1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific11
1CompletedTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
1Not Yet RecruitingTreatmentGastrooesophageal Cancer1
1RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Adenocarcinoma of the Gallbladder / Adenocarcinoma of Unknown Primary / Adult Primary Cholangiocellular Carcinoma / Advanced Adult Primary Liver Cancer / Cholangiocarcinoma of the Extrahepatic Bile Duct / Cholangiocarcinoma of the Gallbladder / Diffuse Adenocarcinoma of the Stomach / Duct Cell Adenocarcinoma of the Pancreas / Intestinal Adenocarcinoma of the Stomach / Localized Unresectable Adult Primary Liver Cancer / Metastatic Carcinoma of Unknown Primary / Metastatic Extrahepatic Bile Duct Cancer / Mixed Adenocarcinoma of the Stomach / Mucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Newly Diagnosed Carcinoma of Unknown Primary / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage III Pancreatic Cancer / Stage IIIA Colon Cancer / Stage IIIA Gallbladder Cancer / Stage IIIA Gastric Cancer / Stage IIIA Rectal Cancer / Stage IIIB Colon Cancer / Stage IIIB Gallbladder Cancer / Stage IIIB Gastric Cancer / Stage IIIB Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Gastric Cancer / Stage IIIC Rectal Cancer / Stage IV Gastric Cancer / Stage IV Pancreatic Cancer / Stage IVA Colon Cancer / Stage IVA Gallbladder Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Gallbladder Cancer / Stage IVB Rectal Cancer / Unresectable Extrahepatic Bile Duct Cancer1
1RecruitingTreatmentAdenocarcinoma of the Rectum / Cancer of Rectum / Cancer of the Rectum / Rectal Carcinoma / Rectum Cancer / Rectum Neoplasms1
1RecruitingTreatmentAdvanced Cancers1
1RecruitingTreatmentAppendix Cancer / Colorectal Cancers / Peritoneal Carcinomatosis1
1RecruitingTreatmentCancer, Breast / Colorectal Cancers / Esophagogastric Cancer / Malignant Neoplasm of Pancreas / Non-Small-Cell Lung Carcinoma (NSCLC) / Tumors1
1RecruitingTreatmentCarcinoma NOS1
1RecruitingTreatmentCholangiocarcinomas / Neoplasms, Hepatic1
1RecruitingTreatmentColorectal Cancers1
1RecruitingTreatmentDigestive Cancers1
1RecruitingTreatmentEsophageal Cancers1
1RecruitingTreatmentHepatocellular,Carcinoma1
1RecruitingTreatmentHodgkins Disease (HD) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphoma, T-Cell, Cutaneous / Lymphoma, T-Cell, Peripheral1
1RecruitingTreatmentLymphoma, B-Cell1
1RecruitingTreatmentMalignant Neoplasm of Pancreas1
1RecruitingTreatmentMedulloblastomas / Neuroblastomas1
1RecruitingTreatmentMetastatic Colorectal Cancers1
1RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
1RecruitingTreatmentPeritoneal Carcinomatosis1
1RecruitingTreatmentRecurrent Non-small Cell Lung Cancer1
1RecruitingTreatmentTumors, Solid2
1SuspendedTreatmentBiliary Tract Carcinoma / Carcinoma of Gallbladder1
1TerminatedTreatmentAdenocarcinoma of the Pancreas / Adenocarcinoma of the Stomach / BRCA1 Mutation Carrier / BRCA2 Mutation Carrier / Ovarian Mucinous Cystadenocarcinoma / Recurrent Breast Cancer / Recurrent Colon Cancer / Recurrent Gastric Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Recurrent Pancreatic Cancer / Recurrent Rectal Cancer / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Stage IV Colon Cancer / Stage IV Gastric Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Ovarian Germ Cell Tumor / Stage IV Pancreatic Cancer / Stage IV Rectal Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers1
1TerminatedTreatmentAdvanced Colorectal Cancer1
1TerminatedTreatmentAngioimmunoblastic T-Cell Lymphoma / B-cell Childhood Acute Lymphoblastic Leukemia / B-Cell Chronic Lymphocytic Leukemia / Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / T-cell Childhood Acute Lymphoblastic Leukemia / T-Cell Large Granular Lymphocyte Leukemia / Unspecified Childhood Solid Tumor, Protocol Specific1
1TerminatedTreatmentColorectal Cancers / Malignant Neoplasm of Stomach1
1TerminatedTreatmentColorectal Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentLung Cancers1
1TerminatedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1TerminatedTreatmentRelapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma1
1TerminatedTreatmentUnspecified Adult Solid Tumor, Protocol Specific2
1Unknown StatusTreatmentNeoplasm, Gastric / Neoplasms, Colorectal / Secondary1
1Unknown StatusTreatmentUnspecified Adult Solid Tumor, Protocol Specific2
1WithdrawnTreatmentLiver Cancer1
1, 2Active Not RecruitingTreatmentAdenocarcinomas / Malignant Neoplasm of Colon / Metastasis / Rectal Carcinoma1
1, 2Active Not RecruitingTreatmentLiver Cancer1
1, 2Active Not RecruitingTreatmentMalignant Neoplasm of Stomach1
1, 2Active Not RecruitingTreatmentMalignant Neoplasm of Stomach / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2Active Not RecruitingTreatmentMetastatic Cancers1
1, 2Active Not RecruitingTreatmentMetastatic Colorectal Cancers1
1, 2Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
1, 2CompletedTreatmentAdenocarcinoma of the Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Diffuse Adenocarcinoma of the Stomach / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Recurrent Esophageal Cancer / Recurrent Gastric Cancer / Stage IV Esophageal Cancer / Stage IV Gastric Cancer1
1, 2CompletedTreatmentAdenocarcinoma of the Pancreas1
1, 2CompletedTreatmentAdenocarcinoma of the Rectum / Stage II Rectal Cancer / Stage III Rectal Cancer1
1, 2CompletedTreatmentBile Duct Neoplasms / Neoplasms, Pancreatic1
1, 2CompletedTreatmentBiliary Tract Cancer / Cholangiocarcinomas / Gallbladder Cancer1
1, 2CompletedTreatmentCancer of the Esophagus1
1, 2CompletedTreatmentCholangiocarcinomas1
1, 2CompletedTreatmentColon/Rectal Cancer / Colon/Rectal Cancer Rectal Cancer / Rectal Carcinoma1
1, 2CompletedTreatmentColorectal Cancers10
1, 2CompletedTreatmentEsophagus Cancer1
1, 2CompletedTreatmentGastrointestinal Diseases1
1, 2CompletedTreatmentGastrooesophageal Cancer / Malignant Solid Tumours1
1, 2CompletedTreatmentLeukemias1
1, 2CompletedTreatmentLeukemias / Richter's Transformation1
1, 2CompletedTreatmentLocally Advanced Pancreatic Cancer / Pancreatic Cancer Metastatic1
1, 2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2CompletedTreatmentMalignant Neoplasm of Stomach1
1, 2CompletedTreatmentMetastatic Colorectal Cancers1
1, 2CompletedTreatmentNeoplasms, Colorectal1
1, 2CompletedTreatmentNeoplasms, Esophageal / Stomach Neoplasms1
1, 2CompletedTreatmentNeoplasms, Pancreatic1
1, 2CompletedTreatmentRectal Neoplasms1
1, 2CompletedTreatmentStage IV Colorectal Cancer1
1, 2Not Yet RecruitingTreatmentCancer, Ovarian1
1, 2Not Yet RecruitingTreatmentCecal Neoplasms / Metastases to peritoneum / Neoplasms, Colorectal / Peritoneal Carcinomatosis1
1, 2Not Yet RecruitingTreatmentColorectal Cancers1
1, 2Not Yet RecruitingTreatmentGastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma1
1, 2Not Yet RecruitingTreatmentNon Hodgkin Lymphoma (NHL)1
1, 2Not Yet RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1, 2RecruitingTreatmentAdenocarcinoma of the Pancreas1
1, 2RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Cardia Adenocarcinoma / Gastroesophageal Junction Adenocarcinoma / Stage IB Gastric Cancer / Stage IB Gastric Cancer AJCC v7 / Stage II Gastric Cancer / Stage II Gastric Cancer AJCC v7 / Stage IIA Gastric Cancer / Stage IIA Gastric Cancer AJCC v7 / Stage IIB Gastric Cancer / Stage IIB Gastric Cancer AJCC v7 / Stage IIIA Gastric Cancer / Stage IIIA Gastric Cancer AJCC v7 / Stage IIIB Gastric Cancer / Stage IIIB Gastric Cancer AJCC v71
1, 2RecruitingTreatmentAdvanced Gastrointestinal Cancers1
1, 2RecruitingTreatmentAdvanced or Metastatic Colorectal Cancer (CRC) / Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Ligand 1 (PD-L1) Inhibitor / Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Protein 1 (PD-1) Inhibitor / Advanced or Metastatic Solid Tumors / Non-Small Cell Lung Cancer (NSCLC; Squamous or Nonsquamous) / Pancreatic Ductal Adenocarcinoma (PDAC)1
1, 2RecruitingTreatmentDigestive Cancers1
1, 2RecruitingTreatmentEsophageal Cancers1
1, 2RecruitingTreatmentGastric Carcinoma1
1, 2RecruitingTreatmentMalignant Neoplasm of Pancreas1
1, 2RecruitingTreatmentMetastatic Pancreas Adenocarcinoma1
1, 2RecruitingTreatmentNeoplasms, Colorectal2
1, 2RecruitingTreatmentPancreatic Cancer Metastatic1
1, 2RecruitingTreatmentRectal Carcinoma1
1, 2SuspendedTreatmentPancreatic Adenocarcinoma Metastatic / Recurrent Pancreatic Carcinoma / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
1, 2TerminatedTreatmentAcute Myeloid Leukaemias (AML) / Leukemias / Myelodysplastic Syndromes1
1, 2TerminatedTreatmentAdenocarcinoma Of Esophagus / Gastric Adenocarcinoma1
1, 2TerminatedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma1
1, 2TerminatedTreatmentColorectal Cancers1
1, 2TerminatedTreatmentEsophageal Cancers1
1, 2TerminatedTreatmentIndolent Lymphoma1
1, 2TerminatedTreatmentMalignant Neoplasm of Pancreas3
1, 2TerminatedTreatmentMalignant Neoplasm of Pancreas / Pancreatic Ductal Adenocarcinoma1
1, 2TerminatedTreatmentMetastatic Colorectal Cancers1
1, 2TerminatedTreatmentPhase I: To Determine the Maximum Tolerated Dose (MTD) / Phase II: To Assess the Pathologic CR Rate and Feasibility Following Neoadjuvant Chemoradiation Therapy With S1/Oxaliplatin1
1, 2TerminatedTreatmentRectal Neoplasms1
1, 2TerminatedTreatmentStage II Rectal Cancer / Stage III Rectal Cancer1
1, 2Unknown StatusTreatmentAdenocarcinoma of the Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Diffuse Adenocarcinoma of the Stomach / Gastrointestinal Cancers / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Stage IIIA Esophageal Cancer / Stage IIIA Gastric Cancer / Stage IIIB Esophageal Cancer / Stage IIIB Gastric Cancer / Stage IIIC Esophageal Cancer / Stage IIIC Gastric Cancer / Stage IV Esophageal Cancer / Stage IV Gastric Cancer1
1, 2Unknown StatusTreatmentCancer, Ovarian1
1, 2Unknown StatusTreatmentColorectal Cancers2
1, 2Unknown StatusTreatmentEsophageal Cancers1
1, 2Unknown StatusTreatmentMelanoma (Skin)1
1, 2Unknown StatusTreatmentRectal Carcinoma1
1, 2WithdrawnTreatmentAdenocarcinoma of the Pancreas / Colon Adenocarcinoma / Pancreatic Adenocarcinoma Metastatic / Pancreatic Ductal Adenocarcinoma / Rectal Adenocarcinoma / Stage III Pancreatic Cancer / Stage IIIA Colon Cancer / Stage IIIA Rectal Cancer / Stage IIIB Colon Cancer / Stage IIIB Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Rectal Cancer / Stage IV Pancreatic Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
1, 2WithdrawnTreatmentColorectal Cancers / Liver Cancer / Metastasis1
1, 2WithdrawnTreatmentMalignant Neoplasm of Pancreas1
2Active Not RecruitingNot AvailableAdenocarcinoma of the Gastro-oesophageal Junction / Metastatic Gastric Cancers1
2Active Not RecruitingTreatmentAdenocarcinoma of the Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Diffuse Adenocarcinoma of the Stomach / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Squamous Cell Carcinoma of the Esophagus / Stage IA Esophageal Cancer / Stage IA Gastric Cancer / Stage IB Esophageal Cancer / Stage IB Gastric Cancer / Stage IIA Esophageal Cancer / Stage IIA Gastric Cancer / Stage IIB Esophageal Cancer / Stage IIB Gastric Cancer / Stage IIIA Esophageal Cancer / Stage IIIA Gastric Cancer / Stage IIIB Esophageal Cancer / Stage IIIB Gastric Cancer / Stage IIIC Esophageal Cancer / Stage IIIC Gastric Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas1
2Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers1
2Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers / Malignant Neoplasm of Stomach2
2Active Not RecruitingTreatmentAdult T-cell lymphomas/leukaemias1
2Active Not RecruitingTreatmentAdvanced Colorectal Cancer1
2Active Not RecruitingTreatmentBiliary Tract Neoplasms1
2Active Not RecruitingTreatmentCLDN18.2-positive Adenocarcinoma of Esophagus / CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction / CLDN18.2-positive Gastric Adenocarcinoma1
2Active Not RecruitingTreatmentCarcinoma of the Appendix / Primary Peritoneal Cavity Cancer1
2Active Not RecruitingTreatmentColorectal Cancer Liver Metastases1
2Active Not RecruitingTreatmentColorectal Cancers5
2Active Not RecruitingTreatmentColorectal Cancers / Metastatic Cancers1
2Active Not RecruitingTreatmentEsophageal Cancers1
2Active Not RecruitingTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach5
2Active Not RecruitingTreatmentGastric Adenocarcinoma With Peritoneal Carcinomatosis / Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis / Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis1
2Active Not RecruitingTreatmentGastric Adenocarcinoma / Neoplasms, Gastrointestinal1
2Active Not RecruitingTreatmentGastrointestinal Cancers1
2Active Not RecruitingTreatmentHepatic Metastases / Rectal Carcinoma1
2Active Not RecruitingTreatmentHepatocellular,Carcinoma1
2Active Not RecruitingTreatmentHer-2 Positive Gastric Cancer / Metastatic or Recurrent Gastric Adenocarcinoma1
2Active Not RecruitingTreatmentMalignant Neoplasm of Esophagus / Malignant Neoplasm of Stomach1
2Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas7
2Active Not RecruitingTreatmentMalignant Neoplasm of Stomach1
2Active Not RecruitingTreatmentMalignant Neoplasm of Stomach / Unresectable1
2Active Not RecruitingTreatmentMetastatic Colorectal Cancers2
2Active Not RecruitingTreatmentMucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic2
2Active Not RecruitingTreatmentPancreatic Cancer Metastatic1
2Active Not RecruitingTreatmentRectal Adenocarcinoma / Stage II Rectal Cancer / Stage II Rectal Cancer AJCC v7 / Stage III Rectal Cancer / Stage III Rectal Cancer AJCC v71
2Active Not RecruitingTreatmentRectal Carcinoma5
2Active Not RecruitingTreatmentRecurrent Small Intestine Cancer / Small Intestine Adenocarcinoma1
2Active Not RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
2AvailableNot AvailableHepatocellular,Carcinoma / Injury; Blood Vessel, Hepatic, Artery1
2CompletedNot AvailableMetastatic Breast Cancer (MBC)1
2CompletedPreventionPancreatic Cancer Metastatic1
2CompletedSupportive CareColorectal Cancers / Nausea and Vomiting1
2CompletedTreatmentAdenocarcinoma Of Esophagus / Gastric Adenocarcinoma1
2CompletedTreatmentAdenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease1
2CompletedTreatmentAdenocarcinoma of Gallbladder / Cholangiocarcinomas1
2CompletedTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Squamous Cell Carcinoma / Recurrent Cervical Carcinoma / Stage IVA Cervical Cancer / Stage IVB Cervical Cancer1
2CompletedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Advanced Colorectal Cancer1
2CompletedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Hepatic Metastases / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2CompletedTreatmentAdenocarcinoma of the Pancreas1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer1
2CompletedTreatmentAdenocarcinoma of the Rectum / Mucinous Adenocarcinoma of the Colon / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2CompletedTreatmentAdenocarcinoma of the Stomach / Adenocarcinomas of the Gastroesophageal Junction / Recurrent Gastric Cancer / Stage IIIA Gastric Cancer / Stage IIIB Gastric Cancer / Stage IIIC Gastric Cancer / Stage IV Gastric Cancer1
2CompletedTreatmentAdenocarcinomas of the Esophagogastric Junction / Malignant Neoplasm of Stomach2
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Diffuse Adenocarcinoma of the Stomach / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Recurrent Gastric Cancer / Stage IIIA Gastric Cancer / Stage IIIB Gastric Cancer / Stage IIIC Gastric Cancer / Stage IV Gastric Cancer1
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Undifferentiated Carcinoma / Gastric Adenocarcinoma / Gastric Squamous Cell Carcinoma / Recurrent Esophageal Adenocarcinoma / Recurrent Esophageal Squamous Cell Carcinoma / Recurrent Gastric Carcinoma / Stage IIIB Esophageal Adenocarcinoma / Stage IIIB Esophageal Squamous Cell Carcinoma / Stage IIIB Gastric Cancer / Stage IIIC Esophageal Adenocarcinoma / Stage IIIC Esophageal Squamous Cell Carcinoma / Stage IIIC Gastric Cancer / Stage IV Esophageal Adenocarcinoma / Stage IV Esophageal Squamous Cell Carcinoma / Stage IV Gastric Cancer / Undifferentiated Gastric Carcinoma1
2CompletedTreatmentAdult Primary Cholangiocellular Carcinoma / Advanced Adult Primary Liver Cancer / Cholangiocarcinoma of the Extrahepatic Bile Duct / Cholangiocarcinoma of the Gallbladder / Localized Unresectable Adult Primary Liver Cancer / Periampullary Adenocarcinoma / Recurrent Adult Primary Liver Cancer / Recurrent Extrahepatic Bile Duct Cancer / Recurrent Gallbladder Cancer / Unresectable Extrahepatic Bile Duct Cancer / Unresectable Gallbladder Cancer1
2CompletedTreatmentAdult Primary Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer1
2CompletedTreatmentAdvanced Biliary Tract Adenocarcinoma / Combination Chemotherapy / Efficacy / Gemcitabine / Oxaliplatin1
2CompletedTreatmentAdvanced Gastric Carcinoma1
2CompletedTreatmentAdvanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment)1
2CompletedTreatmentAnal Carcinoma1
2CompletedTreatmentAngioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentBiliary Carcinoma1
2CompletedTreatmentBiliary Tract Cancer1
2CompletedTreatmentBiliary Tract Cancer / Gallbladder Adenocarcinoma1
2CompletedTreatmentBiliary Tract Cancer / Gallbladder Cancer1
2CompletedTreatmentBiliary Tract Neoplasms1
2CompletedTreatmentBladder Cancers1
2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter1
2CompletedTreatmentBrain and Central Nervous System Tumors1
2CompletedTreatmentCancer of the Biliary Tract / Cancer of the Gallbladder1
2CompletedTreatmentCancer of the Rectum / Colorectal Cancers / Rectal Carcinoma1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentCancer, Ovarian1
2CompletedTreatmentCancer, Ovarian / Primary Peritoneal Cavity Cancer1
2CompletedTreatmentCancers1
2CompletedTreatmentCarcinoma, Colorectal1
2CompletedTreatmentCervical Cancers1
2CompletedTreatmentChildhood Central Nervous System Germ Cell Tumor / Childhood Extragonadal Germ Cell Tumor / Childhood Hepatoblastoma / Childhood Hepatocellular Carcinoma / Childhood High-grade Cerebral Astrocytoma / Childhood Low-grade Cerebral Astrocytoma / Childhood Malignant Ovarian Germ Cell Tumor / Childhood Malignant Testicular Germ Cell Tumor / Childhood Teratoma / Recurrent Adrenocortical Carcinoma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Liver Cancer / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Childhood Visual Pathway and Hypothalamic Glioma / Recurrent Colon Cancer / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Nasopharyngeal Cancer / Recurrent Neuroblastoma / Recurrent Osteosarcoma / Recurrent Rectal Cancer / Recurrent Renal Cell Cancer1
2CompletedTreatmentCholangiocarcinomas2
2CompletedTreatmentColorectal Cancers41
2CompletedTreatmentColorectal Cancers / Hepatic Metastases2
2CompletedTreatmentColorectal Cancers / Metastatic Cancers4
2CompletedTreatmentColorectal Cancers / Neoplasms Metastasis3
2CompletedTreatmentColorectal Cancers / Neoplasms, Colorectal1
2CompletedTreatmentColorectal Cancers / Rectal Carcinoma1
2CompletedTreatmentConcurrent Chemoradiotherapy / Esophageal Cancers / Oxaliplatin / Paclitaxel1
2CompletedTreatmentEndometrial Cancers2
2CompletedTreatmentEsophageal Cancers3
2CompletedTreatmentEsophageal Cancers / Gastrooesophageal Cancer2
2CompletedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach4
2CompletedTreatmentEsophagus Cancer1
2CompletedTreatmentGastric Cancer Adenocarcinoma Metastatic1
2CompletedTreatmentGastric Carcinoma / Gastroesophageal Junction Carcinoma1
2CompletedTreatmentGastric cancer stage IV2
2CompletedTreatmentGastro Oesophageal Cancer1
2CompletedTreatmentGastroesophageal Junction Cancer / Malignant Neoplasm of Stomach1
2CompletedTreatmentGastrointestinal Cancers2
2CompletedTreatmentGastrooesophageal Cancer / Malignant Neoplasm of Stomach1
2CompletedTreatmentGerm Cell Neoplasms / Testicular Cancer1
2CompletedTreatmentHead and Neck Carcinoma4
2CompletedTreatmentHead or Neck Cancer1
2CompletedTreatmentHepatocellular,Carcinoma4
2CompletedTreatmentHormone-Resistant Prostate Cancer / Recurrent Prostate Cancer1
2CompletedTreatmentLiver Cancer2
2CompletedTreatmentLiver Cancer / Malignant Neoplasm of Pancreas1
2CompletedTreatmentLiver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer1
2CompletedTreatmentLocally Advanced Pancreatic Cancer / Nonmetastatic Pancreatic Cancer / Patients With Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer / Unresectable Pancreatic Cancer1
2CompletedTreatmentLocally Advanced / Metastatic / Unresectable1
2CompletedTreatmentLung Cancers2
2CompletedTreatmentLymphoma, B-Cell1
2CompletedTreatmentLymphoma, Large Cell, Diffuse1
2CompletedTreatmentMalignant Neoplasm of Colon3
2CompletedTreatmentMalignant Neoplasm of Nasopharynx1
2CompletedTreatmentMalignant Neoplasm of Pancreas9
2CompletedTreatmentMalignant Neoplasm of Stomach13
2CompletedTreatmentMetastatic Adenocarcinoma of Gastric Cardia / Metastatic Adenocarcinoma of the Esophagus / Unresectable Adenocarcinoma of Gastric Cardia / Unresectable Adenocarcinoma of the Esophagus1
2CompletedTreatmentMetastatic Breast Cancer (MBC)2
2CompletedTreatmentMetastatic Colorectal Cancers14
2CompletedTreatmentMetastatic Transitional Cell Cancer of the Urothelial Tract1
2CompletedTreatmentMixed Mullerian Tumors of the Uterus1
2CompletedTreatmentNasopharyngeal Neoplasms1
2CompletedTreatmentNeoplasms Metastasis / Neoplasms, Colorectal1
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentNeoplasms, Colorectal4
2CompletedTreatmentNeoplasms, Esophageal1
2CompletedTreatmentNeoplasms, Esophageal / Stomach Neoplasms1
2CompletedTreatmentNeoplasms, Germ Cell and Embryonal2
2CompletedTreatmentNeoplasms, Pancreatic2
2CompletedTreatmentNeuroendocrine Tumors1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)8
2CompletedTreatmentOvarian Carcinoma / Relapses1
2CompletedTreatmentPancreatic Acinar Cell Carcinoma / Pancreatic Ductal Adenocarcinoma / Recurrent Pancreatic Carcinoma / Stage IV Pancreatic Cancer1
2CompletedTreatmentPeritoneal Carcinomatosis1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentRectal Adenocarcinoma1
2CompletedTreatmentRectal Carcinoma9
2CompletedTreatmentRectal Neoplasms6
2CompletedTreatmentRectum Cancer1
2CompletedTreatmentRecurrent Extragonadal Seminoma / Recurrent Malignant Extragonadal Germ Cell Tumor / Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor / Recurrent Malignant Testicular Germ Cell Tumor / Recurrent Ovarian Germ Cell Tumor / Stage III Testicular Cancer / Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor / Stage IV Extragonadal Seminoma / Stage IV Ovarian Germ Cell Tumor1
2CompletedTreatmentRefractory Aggressive Non-Hodgkin's Lymphoma / Relapsing Aggressive Non-Hodgkin's Lymphoma1
2CompletedTreatmentStage IV Gastric Cancer With Metastasis1
2CompletedTreatmentStomach Neoplasms8
2CompletedTreatmentUnknown Primary Neoplasms2
2CompletedTreatmentUnresectable Biliary Tract Cancer1
2Enrolling by InvitationTreatmentRectal Carcinoma1
2Enrolling by InvitationTreatmentStomach Neoplasms1
2Not Yet RecruitingPreventionColo-rectal Cancer / Metastases to peritoneum / Peritoneal Carcinomatosis / Peritoneum Cancer1
2Not Yet RecruitingTreatmentCarcinoma, Pancreatic1
2Not Yet RecruitingTreatmentColorectal Adenocarcinoma / Stage IVA Colorectal Cancer / Stage IVB Colorectal Cancer1
2Not Yet RecruitingTreatmentColorectal Cancers1
2Not Yet RecruitingTreatmentGastric cancer stage IV1
2Not Yet RecruitingTreatmentGastro-esophageal Junction Adenocarcinoma / Malignant Neoplasm of Stomach1
2Not Yet RecruitingTreatmentHepatocellular,Carcinoma1
2Not Yet RecruitingTreatmentMalignant Neoplasm of Colorectum1
2Not Yet RecruitingTreatmentMalignant Neoplasm of Pancreas1
2Not Yet RecruitingTreatmentMalignant Neoplasm of Stomach2
2Not Yet RecruitingTreatmentMalignant Neoplasm of Stomach / Stomach Neoplasms1
2Not Yet RecruitingTreatmentMetastatic Colorectal Cancers2
2RecruitingNot AvailablePancreatic Adenocarcinoma Metastatic1
2RecruitingNot AvailableRectal Carcinoma1
2RecruitingPreventionMalignant Neoplasm of Stomach1
2RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IV Pancreatic Cancer1
2RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Stage I Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer1
2RecruitingTreatmentAdenocarcinoma of the Esophagus or Esophagogastric Junction1
2RecruitingTreatmentAdenocarcinoma of the Esophagus / Adenocarcinoma of the Gastric Cardia / Adenocarcinomas of the Gastroesophageal Junction / Stage IIIA Esophageal Cancer / Stage IIIB Esophageal Cancer / Stage IIIC Esophageal Cancer1
2RecruitingTreatmentAdenocarcinoma of the Pancreas1
2RecruitingTreatmentAdenocarcinoma of the Pancreas / Resectable Pancreatic Cancers / Resectable Pancreatic Carcinoma1
2RecruitingTreatmentAdenocarcinoma of the Pancreas / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer1
2RecruitingTreatmentAdenocarcinomas of the Esophagogastric Junction1
2RecruitingTreatmentAggressive Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL)1
2RecruitingTreatmentBiliary Tract Cancer2
2RecruitingTreatmentBorderline Resectable Pancreatic Cancer1
2RecruitingTreatmentCNS Germ Cell Tumor1
2RecruitingTreatmentCancer treatment / Chemoradiotherapy / Neoadjuvant Therapy / Stomach Neoplasms1
2RecruitingTreatmentCholangiocellular Carcinoma / Cholangiolar Carcinoma / Intrahepatic Cholangiocarcinoma / Peripheral Cholangiocarcinoma1
2RecruitingTreatmentColorectal Cancers4
2RecruitingTreatmentColorectal Cancers / Hepatic Metastases1
2RecruitingTreatmentDocetaxel, Oxaliplatin and Fluorouracil1
2RecruitingTreatmentElderly Metastatic Colorectal Cancer Patients1
2RecruitingTreatmentEndostatin / Esophageal Cancers1
2RecruitingTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
2RecruitingTreatmentExtranodal NK/T-cell Lymphoma, Nasal Type1
2RecruitingTreatmentGastroesophageal Junction Adenocarcinoma / Metastatic Gastric Adenocarcinoma1
2RecruitingTreatmentHepatocellular Cancer1
2RecruitingTreatmentHepatocellular,Carcinoma1
2RecruitingTreatmentHepatocellular,Carcinoma / Secondary1
2RecruitingTreatmentLocally Advanced Colorectal Cancer1
2RecruitingTreatmentLocally Advanced Gastric Cancer / Metastatic Gastric Cancers1
2RecruitingTreatmentLymphoma, Extranodal NK-T-Cell1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentMalignant Neoplasm of Pancreas4
2RecruitingTreatmentMalignant Neoplasm of Stomach7
2RecruitingTreatmentMetastatic Colorectal Cancers8
2RecruitingTreatmentMucinous Adenocarcinoma of the Rectum / Signet Ring Adenocarcinoma of the Rectum / Stage IIA Rectal Cancer / Stage IIB Rectal Cancer / Stage IIC Rectal Cancer / Stage IIIA Rectal Cancer / Stage IIIB Rectal Cancer / Stage IIIC Rectal Cancer1
2RecruitingTreatmentNeoplasms, Colorectal2
2RecruitingTreatmentNeoplasms, Esophageal1
2RecruitingTreatmentNeoplasms, Esophageal / Stomach Neoplasms2
2RecruitingTreatmentNeoplasms, Pancreatic1
2RecruitingTreatmentOesophageal Carcinoma1
2RecruitingTreatmentPancreatic Cancer Metastatic1
2RecruitingTreatmentPancreatic Metastatic Cancer / Toxicity1
2RecruitingTreatmentPosttransplant Lymphoproliferative Disorder1
2RecruitingTreatmentRectal Adenocarcinoma / Stage II Rectal Cancer / Stage II Rectal Cancer AJCC v7 / Stage III Rectal Cancer / Stage III Rectal Cancer AJCC v71
2RecruitingTreatmentRectal Carcinoma6
2RecruitingTreatmentRectal Carcinoma / Rectosigmoid Cancer1
2RecruitingTreatmentResectable Pancreatic Ductal Adenocarcinoma1
2RecruitingTreatmentSafety and Effectiveness of Apatinib Combined With SOX Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer1
2RecruitingTreatmentStage III Colon Cancer1
2SuspendedTreatmentBladder Cancers1
2SuspendedTreatmentMalignant Neoplasm of Stomach1
2TerminatedTreatmentAbdominal wall neoplasm1
2TerminatedTreatmentAdenocarcinoma of the Pancreas1
2TerminatedTreatmentAdenocarcinoma of the Pancreas / Poorly Differentiated Malignant Neoplasm / Resectable Pancreatic Cancers / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer / Undifferentiated Pancreatic Carcinoma1
2TerminatedTreatmentAdenocarcinomas / Malignant Neoplasm of Colon1
2TerminatedTreatmentAppendix Tumors / Colon Tumors / Endocrine Tumors / Peritoneum Tumors / Rectum Tumors1
2TerminatedTreatmentBiliary Tract Cancer1
2TerminatedTreatmentCancer, Breast2
2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
2TerminatedTreatmentCancers of the Head and Neck1
2TerminatedTreatmentCancers of the Head and Neck / Neoplasms, Head and Neck1
2TerminatedTreatmentCarcinoma of the Head and Neck1
2TerminatedTreatmentColorectal Cancers8
2TerminatedTreatmentColorectal Cancers / Metastases1
2TerminatedTreatmentColorectal Cancers / Metastatic Cancers1
2TerminatedTreatmentColorectal Cancers / Neoplasms Metastasis1
2TerminatedTreatmentColorectal Liver Metastases1
2TerminatedTreatmentEsophageal Cancers2
2TerminatedTreatmentGastric Adenocarcinoma1
2TerminatedTreatmentHER2 Positive Esophagogastric Cancer1
2TerminatedTreatmentHead and Neck Carcinoma1
2TerminatedTreatmentHead and Neck Carcinoma / Squamous Carcinoma1
2TerminatedTreatmentHepatic Metastases / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2TerminatedTreatmentHepatic Metastases / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
2TerminatedTreatmentHepatocellular Cancer / Liver Cancer1
2TerminatedTreatmentHepatocellular,Carcinoma1
2TerminatedTreatmentKRAS Wild Type / Resectable Type II Gastric Adenocarcinoma1
2TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2TerminatedTreatmentLung Cancers1
2TerminatedTreatmentLymphoma, Extranodal NK-T-Cell1
2TerminatedTreatmentMalignant Neoplasm of Pancreas3
2TerminatedTreatmentMalignant Neoplasm of Pancreas / Pancreatic Carcinoma Non-resectable1
2TerminatedTreatmentMalignant Neoplasm of Stomach2
2TerminatedTreatmentMetastastic Breast Cancer / Recurrent Breast Cancer1
2TerminatedTreatmentMetastatic Breast Cancer (MBC)1
2TerminatedTreatmentMetastatic Colorectal Cancers2
2TerminatedTreatmentNasopharyngeal Carcinoma1
2TerminatedTreatmentNeoplasm Metastases / Neoplasms, Colorectal1
2TerminatedTreatmentNeoplasms, Breast1
2TerminatedTreatmentNeoplasms, Colorectal5
2TerminatedTreatmentNeoplasms / Neoplasms, Head and Neck1
2TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2TerminatedTreatmentPatients With Colorectal Cancer With Unresectable Synchronous Metastasis in Whom Resection of the Primitive Tumour is Indicated1
2TerminatedTreatmentRectal Neoplasms1
2TerminatedTreatmentRecurrent Ovarian Epithelial Cancer1
2TerminatedTreatmentStage IB Esophageal Adenocarcinoma / Stage IIA Esophageal Adenocarcinoma / Stage IIB Esophageal Adenocarcinoma / Stage IIIA Esophageal Adenocarcinoma / Stage IIIB Esophageal Adenocarcinoma / Stage IIIC Esophageal Adenocarcinoma1
2TerminatedTreatmentStage IV Colon Cancer / Stage IV Rectal Cancer1
2TerminatedTreatmentTransitional Cell Carcinoma1
2TerminatedTreatmentUterine Neoplasms1
2Unknown StatusBasic ScienceMetastatic Colorectal Cancers1
2Unknown StatusDiagnosticColorectal Cancers1
2Unknown StatusTreatmentAdenocarcinoma of the Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Stage II Esophageal Cancer1
2Unknown StatusTreatmentAdenocarincoma of Pancreas / Stage III Pancreatic Cancer / Stage IVA Pancreatic Cancer / Stage IVB Pancreatic Cancer1
2Unknown StatusTreatmentAdvanced Hepatocellular Carcinoma / Metastatic Hepatocellular Carcinoma1
2Unknown StatusTreatmentAfter Resection of Liver Metastases / Colorectal Cancers / KRAS Wildtype1
2Unknown StatusTreatmentBiliary Tract Cancer2
2Unknown StatusTreatmentBiliary Tract Cancer / Gallbladder Adenocarcinoma1
2Unknown StatusTreatmentBiliary Tract Cancer / Malignant Neoplasm of Pancreas / Periampullary Adenocarcinoma1
2Unknown StatusTreatmentCancer, Ovarian1
2Unknown StatusTreatmentCarcinoma, Large Cell / Non-Small-Cell Lung Carcinoma (NSCLC) / Squamous Carcinoma1
2Unknown StatusTreatmentChemotherapeutic Agent Toxicity / Colorectal Cancers / Neurotoxicity1
2Unknown StatusTreatmentCholangiocarcinomas1
2Unknown StatusTreatmentColorecal Neoplasms / Secondary1
2Unknown StatusTreatmentColorectal Cancers9
2Unknown StatusTreatmentColorectal Cancers / Metastatic Cancers4
2Unknown StatusTreatmentColorectal Cancers / Peritoneal Cavity Cancer1
2Unknown StatusTreatmentCuratively-resected, Node-positive Esophageal Squamous Cell Carcinoma1
2Unknown StatusTreatmentERCC1 / Pancreatic Cancer Metastatic1
2Unknown StatusTreatmentElderly / First-Line / Malignant Neoplasm of Stomach / Oxaliplatin / S-11
2Unknown StatusTreatmentFallopian Tube Carcinoma / Ovarian Carcinoma / Primary Peritoneal Cancer1
2Unknown StatusTreatmentGastric Adenocarcinoma1
2Unknown StatusTreatmentGastric cancer stage IV1
2Unknown StatusTreatmentHead and Neck Carcinoma1
2Unknown StatusTreatmentHepatic Lesions / Hepatic Metastases / Metastatic Colorectal Cancers1
2Unknown StatusTreatmentHepatic Metastases / Metastatic Breast Cancer (MBC)2
2Unknown StatusTreatmentInoperable Esophageal Cancer Stage I-III1
2Unknown StatusTreatmentLiver Cancer2
2Unknown StatusTreatmentLiver Metastasis1
2Unknown StatusTreatmentLocally Advanced Pancreatic Cancer1
2Unknown StatusTreatmentLocally Advanced Rectal Cancer1
2Unknown StatusTreatmentLung Cancers2
2Unknown StatusTreatmentMalignant Lymphomas1
2Unknown StatusTreatmentMalignant Neoplasm of Esophagus1
2Unknown StatusTreatmentMalignant Neoplasm of Pancreas3
2Unknown StatusTreatmentMalignant Neoplasm of Stomach6
2Unknown StatusTreatmentMalignant Neoplasm of Stomach / Metastases to Perineum1
2Unknown StatusTreatmentMesothelioma2
2Unknown StatusTreatmentMetastatic Breast Cancer (MBC) / Recurrent Breast Cancer1
2Unknown StatusTreatmentMetastatic Colorectal Cancers3
2Unknown StatusTreatmentNasopharyngeal Neoplasms1
2Unknown StatusTreatmentNeoplasms, Colorectal1
2Unknown StatusTreatmentNeoplasms, Colorectal / Neoplasms, Hepatic1
2Unknown StatusTreatmentNon-Hodgkin's Lymphoma (NHL)1
2Unknown StatusTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2Unknown StatusTreatmentPancreas Neoplasms1
2Unknown StatusTreatmentPreviously Treated Metastatic Non-Small Cell Lung Cancer1
2Unknown StatusTreatmentRectal Carcinoma1
2Unknown StatusTreatmentRecurrent / Stage IV / Stomach Neoplasms1
2Unknown StatusTreatmentRefractory Solid Tumors / Relapsed Solid Tumors1
2Unknown StatusTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
2WithdrawnTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum1
2WithdrawnTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
2WithdrawnTreatmentAdenocarcinoma of the Pancreas1
2WithdrawnTreatmentCholangiocarcinomas1
2WithdrawnTreatmentColorectal Cancers2
2WithdrawnTreatmentColorectal Cancers / Metastatic Cancers2
2WithdrawnTreatmentEsophagogastric Adenocarcinoma / Metastatic Disease / No Previous Chemotherapy for Metastatic Esophagogastric Cancer1
2WithdrawnTreatmentEsophagogastric Cancer1
2WithdrawnTreatmentMetastatic Colorectal Cancers4
2WithdrawnTreatmentNeoplasms, Colorectal1
2, 3Active Not RecruitingTreatmentCarcinoid tumour of the gastrointestinal tract / Islet Cell Tumor / Lung Cancers / Neoplastic Syndrome / Neuroendocrine Tumors1
2, 3Active Not RecruitingTreatmentColorectal Cancers1
2, 3Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2, 3Active Not RecruitingTreatmentMalignant Neoplasm of Stomach1
2, 3Active Not RecruitingTreatmentRectal Carcinoma1
2, 3CompletedDiagnosticColorectal Cancers1
2, 3CompletedTreatmentColorectal Cancers1
2, 3CompletedTreatmentEsophageal Cancers1
2, 3CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer1
2, 3CompletedTreatmentMalignant Neoplasm of Stomach1
2, 3Not Yet RecruitingTreatmentAbdominal wall neoplasm / Carcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Neoplasms, Colorectal / Peritoneal Diseases1
2, 3Not Yet RecruitingTreatmentColorectal Cancers1
2, 3Not Yet RecruitingTreatmentHepatocellular,Carcinoma1
2, 3Not Yet RecruitingTreatmentResected Liver Metastases From Colorectal Cancer1
2, 3RecruitingTreatmentColorectal Cancers1
2, 3RecruitingTreatmentEffects of Chemotherapy / General Surgery / Malignant Neoplasm of Stomach1
2, 3RecruitingTreatmentGastroesophageal Junction Adenocarcinoma2
2, 3RecruitingTreatmentGastroesophageal Junction Cancer / Malignant Neoplasm of Stomach1
2, 3RecruitingTreatmentMalignant Neoplasm of Pancreas1
2, 3RecruitingTreatmentMalignant Neoplasm of Stomach2
2, 3RecruitingTreatmentRectal Carcinoma1
2, 3RecruitingTreatmentResectable Prancreas Carcinoma1
2, 3Unknown StatusDiagnosticColorectal Cancers1
2, 3Unknown StatusTreatmentC04.588.274.476.411.3071
2, 3Unknown StatusTreatmentColorectal Cancers2
2, 3Unknown StatusTreatmentMalignant Neoplasm of Pancreas1
2, 3Unknown StatusTreatmentRectal Carcinoma1
2, 3WithdrawnTreatmentCarcinoma, Colorectal / Hepatic Metastases1
3Active Not RecruitingTreatmentBorderline Ovarian Mucinous Tumor / Ovarian Mucinous Cystadenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Stage IA Fallopian Tube Cancer / Stage IA Ovarian Cancer / Stage IB Fallopian Tube Cancer / Stage IB Ovarian Cancer / Stage IC Fallopian Tube Cancer / Stage IC Ovarian Cancer / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Cancer / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Cancer / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer1
3Active Not RecruitingTreatmentCRC1
3Active Not RecruitingTreatmentCognitive/Functional Effects / Colorectal Cancers / Neurotoxicity1
3Active Not RecruitingTreatmentColon Mucinous Adenocarcinoma / Colon Signet Ring Cell Adenocarcinoma / Lynch Syndrome / Stage IIA Colon Cancer / Stage IIB Colon Cancer / Stage IIC Colon Cancer1
3Active Not RecruitingTreatmentColorectal Cancers4
3Active Not RecruitingTreatmentGastric Adenocarcinoma1
3Active Not RecruitingTreatmentLocally Advanced Malignant Neoplasm / Malignant Neoplasm of Pancreas / Pancreatic Carcinoma Non-resectable1
3Active Not RecruitingTreatmentMalignant Neoplasm of Stomach2
3Active Not RecruitingTreatmentMetastatic Colorectal Cancers2
3Active Not RecruitingTreatmentNeoplasms, Gastrointestinal Tract1
3CompletedPreventionCancers1
3CompletedPreventionCarcinoma, Colorectal / Metastases / Neoplasms, Colorectal1
3CompletedPreventionPain / Pain, Neuropathic / Polyneuropathies1
3CompletedSupportive CareChemotherapeutic Agent Toxicity / Colorectal Cancers / Neuropathy / Neurotoxicity1
3CompletedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage III Colon Cancer / Stage III Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
3CompletedTreatmentAdenocarcinoma of the Colon / Stage IIA Colon Cancer / Stage IIB Colon Cancer / Stage IIC Colon Cancer / Stage IIIA Colon Cancer / Stage IIIB Colon Cancer / Stage IIIC Colon Cancer1
3CompletedTreatmentAdenocarcinoma of the Colon / Stage III Colon Cancer1
3CompletedTreatmentAdverse Drug Events / Complications / Hospital Costs / Length of Stay / Quality of Life1
3CompletedTreatmentColonic Neoplasms1
3CompletedTreatmentColorectal Cancers17
3CompletedTreatmentColorectal Cancers / Metastasis1
3CompletedTreatmentColorectal Cancers / Primary Peritoneal Cavity Cancer1
3CompletedTreatmentColorectal Peritoneal Carcinomatosis1
3CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer1
3CompletedTreatmentHepatocellular,Carcinoma1
3CompletedTreatmentMalignant Neoplasm of Colon1
3CompletedTreatmentMalignant Neoplasm of Pancreas1
3CompletedTreatmentMalignant Neoplasm of Stomach4
3CompletedTreatmentMetastatic Colorectal Cancers4
3CompletedTreatmentMucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IIIA Colon Cancer / Stage IIIA Rectal Cancer / Stage IIIB Colon Cancer / Stage IIIB Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
3CompletedTreatmentNeoplasms, Pancreatic1
3CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
3CompletedTreatmentRectal Neoplasms1
3CompletedTreatmentStage II Colon Cancer / Stage III Colon Cancer1
3CompletedTreatmentStomach Neoplasms1
3CompletedTreatmentUnresectable, Metastatic Biliary Tract Carcinoma1
3Enrolling by InvitationTreatmentMalignant Neoplasm of Stomach1
3Not Yet RecruitingPreventionIntraperitoneal Rectal Cancer / Malignant Neoplasm of Colon1
3Not Yet RecruitingTreatmentColorectal Adenocarcinoma / High-Frequency Microsatellite Instability / Stage IV Colorectal Cancer / Stage IV Colorectal Cancer AJCC v7 / Stage IVA Colorectal Cancer / Stage IVA Colorectal Cancer AJCC v7 / Stage IVB Colorectal Cancer / Stage IVB Colorectal Cancer AJCC v71
3Not Yet RecruitingTreatmentColorectal Cancers1
3Not Yet RecruitingTreatmentHepatoblastomas / Hepatocellular,Carcinoma1
3Not Yet RecruitingTreatmentMetastatic Colorectal Cancers1
3RecruitingPreventionAbdominal wall neoplasm / Neoplasms, Colorectal1
3RecruitingPreventionCholangiocarcinomas1
3RecruitingTreatmentAdenocarcinomas of the Esophagogastric Junction / Esophageal Adenocarcinoma (UICC TNM7)1
3RecruitingTreatmentAdenocarcinomas / Chemoradiation / Gastrooesophageal Cancer / Locally Advanced Cancer / Stomach Neoplasms1
3RecruitingTreatmentAdvanced Rectal Cancer1
3RecruitingTreatmentAmpullary Cancer / Biliary Tract Cancer / Cholangiocarcinomas / Gallbladder Cancer1
3RecruitingTreatmentBiliary Tract (Intrahepatic, Extrahepatic Cholangiocarcinoma, Gall Bladder) Cancer1
3RecruitingTreatmentCarcinoma NOS / Malignant Neoplasm of Pancreas1
3RecruitingTreatmentChemotherapeutic Toxicity / Chemotherapy Effect / Stomach Neoplasms1
3RecruitingTreatmentColon Adenocarcinoma / DNA Repair Disorder / Lynch Syndrome / Microsatellite Instability / Stage III Colon Cancer AJCC v7 / Stage IIIA Colon Cancer / Stage IIIA Colon Cancer AJCC v7 / Stage IIIB Colon Cancer / Stage IIIB Colon Cancer AJCC v7 / Stage IIIC Colon Cancer / Stage IIIC Colon Cancer AJCC v71
3RecruitingTreatmentColorectal Cancers1
3RecruitingTreatmentColorectal Cancers / Metastasis1
3RecruitingTreatmentEffects of Chemotherapy / Effects of Radiation Therapy / General Surgery / Neoplasms, Colorectal1
3RecruitingTreatmentExtranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type1
3RecruitingTreatmentGastric Adenocarcinoma1
3RecruitingTreatmentGastric Cancer, Adjuvant Chemotherapy, XO1
3RecruitingTreatmentGastroesophageal Junction Cancer / Malignant Neoplasm of Stomach1
3RecruitingTreatmentHepatocellular,Carcinoma3
3RecruitingTreatmentLocally Advanced Rectal Cancer1
3RecruitingTreatmentLocally Advanced Unresectable Gastric Cancer / Metastatic Gastric Cancers1
3RecruitingTreatmentLymphoma, Extranodal NK-T-Cell1
3RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
3RecruitingTreatmentMalignant Lymphomas1
3RecruitingTreatmentMalignant Neoplasm of Colon3
3RecruitingTreatmentMalignant Neoplasm of Pancreas2
3RecruitingTreatmentMalignant Neoplasm of Stomach8
3RecruitingTreatmentMalignant Neoplasm of Stomach / Stomach Neoplasms1
3RecruitingTreatmentMetastatic Colorectal Cancers1
3RecruitingTreatmentNeoplasms, Colorectal1
3RecruitingTreatmentNeoplasms, Esophageal / Stage III Esophageal Squamous Cell Carcinoma1
3RecruitingTreatmentOESOPHAGO-GASTRIC CARCINOMA1
3RecruitingTreatmentRectal Neoplasms1
3RecruitingTreatmentStage II Esophageal Squamous Cell Carcinoma / Stage III Esophageal Squamous Cell Carcinoma1
3RecruitingTreatmentStage ⅡA Pancreatic Cancer / Stage ⅡB Pancreatic Cancer1
3RecruitingTreatmentStomach Neoplasms1
3RecruitingTreatmentUnresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction1
3SuspendedTreatmentMetastatic Colorectal Cancers1
3TerminatedPreventionHepatocellular,Carcinoma / Liver Cirrhosis / Neoplasm Recurrence, Local / Neoplasms, Hepatic / Recurrences1
3TerminatedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage III Colon Cancer / Stage III Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
3TerminatedTreatmentAdenocarcinoma of the Rectum / Stage II Rectal Cancer / Stage III Rectal Cancer1
3TerminatedTreatmentColorectal Cancers1
3TerminatedTreatmentColorectal Cancers / Hepatic Metastases1
3TerminatedTreatmentColorectal Cancers / Metastatic Cancers1
3TerminatedTreatmentMucinous Adenocarcinoma of the Rectum / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Rectum / Stage IIA Rectal Cancer / Stage IIB Rectal Cancer / Stage IIC Rectal Cancer / Stage IIIA Rectal Cancer / Stage IIIB Rectal Cancer / Stage IIIC Rectal Cancer / Stage IVA Rectal Cancer / Stage IVB Rectal Cancer1
3TerminatedTreatmentOesophago-gastric Cancer1
3Unknown StatusTreatmentAggressive B Cell Lymphoma1
3Unknown StatusTreatmentColorectal Cancers8
3Unknown StatusTreatmentColorectal Cancers / Metastatic Cancers2
3Unknown StatusTreatmentExtragonadal Germ Cell Tumor / Teratoma / Testicular germ cell tumour1
3Unknown StatusTreatmentGastric Adenocarcinoma1
3Unknown StatusTreatmentHepatic Metastases / Neoplasms, Colorectal1
3Unknown StatusTreatmentMalignant Neoplasm of Pancreas3
3Unknown StatusTreatmentMalignant Neoplasm of Stomach1
3Unknown StatusTreatmentMetastatic Pancreas Cancer1
3WithdrawnTreatmentHepatic neoplasms malignant1
4CompletedTreatmentColonic Neoplasms1
4CompletedTreatmentColorectal Cancers2
4CompletedTreatmentColorectal Cancers / Cytokine-Induced Killer Cells / Postoperative Complications / Survival1
4RecruitingTreatmentAdenocarcinoma Of Esophagus / Gastric Adenocarcinoma / Stage IIB Gastric Cancer / Stage IIIA Esophageal Adenocarcinoma / Stage IIIA Gastric Cancer / Stage IIIB Esophageal Adenocarcinoma / Stage IIIB Gastric Cancer / Stage IIIC Esophageal Adenocarcinoma / Stage IIIC Gastric Cancer1
4RecruitingTreatmentAdvanced Adult Primary Liver Cancer1
4RecruitingTreatmentColon Cancer Liver Metastasis1
4RecruitingTreatmentMetastatic Colorectal Cancers1
4TerminatedTreatmentColorectal Cancers1
4Unknown StatusTreatmentCancers1
4Unknown StatusTreatmentColorectal Cancers1
4Unknown StatusTreatmentLiver Metastasis / Malignant Neoplasm of Stomach1
4Unknown StatusTreatmentNeoplasms Metastasis / Neoplasms, Colorectal / Neoplasms, Hepatic1
Not AvailableActive Not RecruitingNot AvailableStage IV Gastric Cancer With Metastasis1
Not AvailableActive Not RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer1
Not AvailableActive Not RecruitingTreatmentLocalized Pancreas Cancer / Malignant Neoplasm of Pancreas / Non-metastatic Pancreas Cancer1
Not AvailableActive Not RecruitingTreatmentMalignant Neoplasm of Pancreas1
Not AvailableApproved for MarketingNot AvailableMalignant Neoplasm of Pancreas1
Not AvailableCompletedNot AvailableColorectal Cancers2
Not AvailableCompletedNot AvailableComplement Component Deficiency / General Surgery / Malignant Neoplasm of Stomach1
Not AvailableCompletedTreatmentCancers / Colonic Diseases1
Not AvailableCompletedTreatmentColorectal Cancers3
Not AvailableCompletedTreatmentColorectal Cancers / Liver Metastasis1
Not AvailableCompletedTreatmentMalignant Neoplasm of Pancreas1
Not AvailableCompletedTreatmentMetastatic Colorectal Cancers1
Not AvailableCompletedTreatmentRectal Carcinoma1
Not AvailableNot Yet RecruitingNot AvailableCancer of Lymph Node / Stomach Neoplasms1
Not AvailableNot Yet RecruitingTreatmentAdvanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction1
Not AvailableRecruitingNot AvailableAdults / Colorectal Cancer Survivors / Oxaliplatin Regimen1
Not AvailableRecruitingSupportive CareMetastatic Gastric Cancers1
Not AvailableRecruitingTreatmentAdenocarcinomas1
Not AvailableRecruitingTreatmentAdvanced Primary Liver Cancer1
Not AvailableRecruitingTreatmentColon Adenocarcinoma1
Not AvailableRecruitingTreatmentMalignant Neoplasm of Pancreas1
Not AvailableRecruitingTreatmentPancreatic Ductal Adenocarcinoma (PDAC)1
Not AvailableTerminatedTreatmentAdenocarcinoma Of Esophagus1
Not AvailableTerminatedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
Not AvailableUnknown StatusNot AvailableMalignant Neoplasm of Colon / Rectal Carcinoma1
Not AvailableUnknown StatusTreatmentChemotherapy, Adjuvant / Hepatocellular,Carcinoma / Survival / Transplantation, Liver / Tumor Recurrence and Metastasis1
Not AvailableUnknown StatusTreatmentHead and Neck Carcinoma1
Pharmacoeconomics
Manufacturers
  • Sanofi aventis us llc
  • App pharmaceuticals llc
  • Ebewe pharma ges mbh nfg kg
  • Fresenius kabi oncology plc
  • Hospira inc
  • Hospira worldwide pty
  • Sun pharma global inc
  • Teva parenteral medicines inc
Packagers
Dosage forms
FormRouteStrength
Injection, solution, concentrateIntravenous5 mg/mL
SolutionIntravenous5 mg
InjectionIntravenous5 mg/mL
Injection, powder, lyophilized, for solutionIntravenous100 mg/20mL
Injection, powder, lyophilized, for solutionIntravenous5 mg/mL
Injection, powder, lyophilized, for solutionIntravenous50 mg/10mL
Injection, solutionIntravenous100 mg/20mL
Injection, solutionIntravenous200 mg/40mL
Injection, solutionIntravenous5 mg/mL
Injection, solutionIntravenous50 mg/10mL
Injection, solution, concentrateIntravenous100 mg/20mL
Injection, solution, concentrateIntravenous50 mg/10mL
Powder, for solutionIntravenous100 mg/20mL
Powder, for solutionIntravenous50 mg/10mL
Powder, for solutionIntravenous100 mg
Powder, for solutionIntravenous50 mg
SolutionIntravenous5.0 mg
Prices
Unit descriptionCostUnit
Oxaliplatin 100 mg vial1650.0USD vial
Oxaliplatin 50 mg vial825.0USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5290961 No1993-01-122013-01-12Us
CA2196922 No2004-06-012015-08-07Canada
US5420319 Yes1997-02-092017-02-09Us
US5716988 Yes1996-02-072016-02-07Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility27.5 mg/mLALOGPS
logP-0.47ALOGPS
logS-1.2ALOGPS
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area85.82 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity67.52 m3·mol-1ChemAxon
Polarizability21.9 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8638
Blood Brain Barrier+0.7667
Caco-2 permeable-0.6453
P-glycoprotein substrateSubstrate0.5056
P-glycoprotein inhibitor INon-inhibitor0.9332
P-glycoprotein inhibitor IINon-inhibitor1.0
Renal organic cation transporterNon-inhibitor0.9289
CYP450 2C9 substrateNon-substrate0.8846
CYP450 2D6 substrateNon-substrate0.8094
CYP450 3A4 substrateNon-substrate0.6064
CYP450 1A2 substrateNon-inhibitor0.8403
CYP450 2C9 inhibitorNon-inhibitor0.8686
CYP450 2D6 inhibitorNon-inhibitor0.8997
CYP450 2C19 inhibitorNon-inhibitor0.8189
CYP450 3A4 inhibitorNon-inhibitor0.8337
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9872
Ames testNon AMES toxic0.6034
CarcinogenicityNon-carcinogens0.938
BiodegradationNot ready biodegradable0.9796
Rat acute toxicity2.3765 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8879
hERG inhibition (predictor II)Non-inhibitor0.938
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cyclohexylamines. These are organic compounds containing a cyclohexylamine moiety, which consist of a cyclohexane ring attached to an amine group.
KingdomOrganic compounds
Super ClassOrganic nitrogen compounds
ClassOrganonitrogen compounds
Sub ClassCyclohexylamines
Direct ParentCyclohexylamines
Alternative ParentsDicarboxylic acids and derivatives / Carboxylic acid salts / Organic transition metal salts / Carboxylic acids / Organic oxides / Monoalkylamines / Hydrocarbon derivatives / Carbonyl compounds / Organic cations
SubstituentsCyclohexylamine / Dicarboxylic acid or derivatives / Carboxylic acid salt / Carboxylic acid derivative / Carboxylic acid / Organic transition metal salt / Amine / Carbonyl group / Primary amine / Organooxygen compound
Molecular FrameworkNot Available
External Descriptorsplatinum coordination entity (CHEBI:31941 )

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
cross-linking/alkylation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Sharma S, Gong P, Temple B, Bhattacharyya D, Dokholyan NV, Chaney SG: Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamics. J Mol Biol. 2007 Nov 9;373(5):1123-40. Epub 2007 Aug 23. [PubMed:17900616 ]
  4. Zhu G, Chang P, Lippard SJ: Recognition of platinum-DNA damage by poly(ADP-ribose) polymerase-1. Biochemistry. 2010 Jul 27;49(29):6177-83. doi: 10.1021/bi100775t. [PubMed:20550106 ]
  5. Ramachandran S, Temple BR, Chaney SG, Dokholyan NV: Structural basis for the sequence-dependent effects of platinum-DNA adducts. Nucleic Acids Res. 2009 May;37(8):2434-48. doi: 10.1093/nar/gkp029. Epub 2009 Mar 2. [PubMed:19255091 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Uniprot Name:
Cytochrome P450 1A1
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Uniprot Name:
Cytochrome P450 1A2
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Uniprot Name:
Cytochrome P450 1B1
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Song IS, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ, Kuo MT: Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther. 2004 Dec;3(12):1543-9. [PubMed:15634647 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Uniprot Name:
Cytochrome P450 2E1
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glutathione transferase activity
Specific Function:
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Acts on 1,2-epoxy-3-(4-nitrophenoxy)propane, phenethylisothiocyanate 4-nitrobenzyl chloride and 4-nitrophenethyl bromide. Displays glutathione peroxidase activity with cumene hydroperoxide.
Gene Name:
GSTT1
Uniprot ID:
P30711
Uniprot Name:
Glutathione S-transferase theta-1
Molecular Weight:
27334.755 Da
References
  1. Link [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Zinc ion binding
Specific Function:
Metallothioneins have a high content of cysteine residues that bind various heavy metals; these proteins are transcriptionally regulated by both heavy metals and glucocorticoids.
Gene Name:
MT1A
Uniprot ID:
P04731
Uniprot Name:
Metallothionein-1A
Molecular Weight:
6120.19 Da
References
  1. Link [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Zinc ion binding
Specific Function:
Metallothioneins have a high content of cysteine residues that bind various heavy metals; these proteins are transcriptionally regulated by both heavy metals and glucocorticoids.
Gene Name:
MT2A
Uniprot ID:
P02795
Uniprot Name:
Metallothionein-2
Molecular Weight:
6042.05 Da
References
  1. Link [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Peroxidase activity
Specific Function:
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.
Gene Name:
MPO
Uniprot ID:
P05164
Uniprot Name:
Myeloperoxidase
Molecular Weight:
83867.71 Da
References
  1. Link [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Zinc ion binding
Specific Function:
Destroys radicals which are normally produced within the cells and which are toxic to biological systems.
Gene Name:
SOD1
Uniprot ID:
P00441
Uniprot Name:
Superoxide dismutase [Cu-Zn]
Molecular Weight:
15935.685 Da
References
  1. Link [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
S-nitrosoglutathione binding
Specific Function:
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration.
Gene Name:
GSTP1
Uniprot ID:
P09211
Uniprot Name:
Glutathione S-transferase P
Molecular Weight:
23355.625 Da
References
  1. Link [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein homodimerization activity
Specific Function:
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.
Gene Name:
GSTM1
Uniprot ID:
P09488
Uniprot Name:
Glutathione S-transferase Mu 1
Molecular Weight:
25711.555 Da
References
  1. Link [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Superoxide dismutase activity
Specific Function:
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinons involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis.
Gene Name:
NQO1
Uniprot ID:
P15559
Uniprot Name:
NAD(P)H dehydrogenase [quinone] 1
Molecular Weight:
30867.405 Da
References
  1. Link [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Uniprot Name:
Solute carrier family 22 member 2
Molecular Weight:
62579.99 Da
References
  1. Burger H, Zoumaro-Djayoon A, Boersma AW, Helleman J, Berns EM, Mathijssen RH, Loos WJ, Wiemer EA: Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol. 2010 Feb;159(4):898-908. doi: 10.1111/j.1476-5381.2009.00569.x. Epub 2010 Jan 8. [PubMed:20067471 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Uniprot Name:
Solute carrier family 22 member 1
Molecular Weight:
61153.345 Da
References
  1. Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergstrom CA, Artursson P: Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem. 2008 Oct 9;51(19):5932-42. doi: 10.1021/jm8003152. Epub 2008 Sep 13. [PubMed:18788725 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Copper uptake transmembrane transporter activity
Specific Function:
High-affinity, saturable copper transporter involved in dietary copper uptake.
Gene Name:
SLC31A1
Uniprot ID:
O15431
Uniprot Name:
High affinity copper uptake protein 1
Molecular Weight:
21090.545 Da
References
  1. Howell SB, Safaei R, Larson CA, Sailor MJ: Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol. 2010 Jun;77(6):887-94. doi: 10.1124/mol.109.063172. Epub 2010 Feb 16. [PubMed:20159940 ]
  2. Song IS, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ, Kuo MT: Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther. 2004 Dec;3(12):1543-9. [PubMed:15634647 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxin transporter activity
Specific Function:
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name:
SLC22A3
Uniprot ID:
O75751
Uniprot Name:
Solute carrier family 22 member 3
Molecular Weight:
61279.485 Da
References
  1. Yokoo S, Masuda S, Yonezawa A, Terada T, Katsura T, Inui K: Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab Dispos. 2008 Nov;36(11):2299-306. doi: 10.1124/dmd.108.023168. Epub 2008 Aug 18. [PubMed:18710896 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Uniprot Name:
ATP-binding cassette sub-family G member 2
Molecular Weight:
72313.47 Da
References
  1. Ceckova M, Vackova Z, Radilova H, Libra A, Buncek M, Staud F: Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP. Toxicol In Vitro. 2008 Dec;22(8):1846-52. doi: 10.1016/j.tiv.2008.09.001. Epub 2008 Sep 9. [PubMed:18801423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Uniprot Name:
Canalicular multispecific organic anion transporter 1
Molecular Weight:
174205.64 Da
References
  1. Link [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Copper-exporting atpase activity
Specific Function:
Involved in the export of copper out of the cells, such as the efflux of hepatic copper into the bile.
Gene Name:
ATP7B
Uniprot ID:
P35670
Uniprot Name:
Copper-transporting ATPase 2
Molecular Weight:
157261.34 Da
References
  1. Link [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Superoxide dismutase copper chaperone activity
Specific Function:
May supply copper to copper-requiring proteins within the secretory pathway, when localized in the trans-Golgi network. Under conditions of elevated extracellular copper, it relocalized to the plasma membrane where it functions in the efflux of copper from cells.
Gene Name:
ATP7A
Uniprot ID:
Q04656
Uniprot Name:
Copper-transporting ATPase 1
Molecular Weight:
163372.275 Da
References
  1. Link [Link]
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:28